Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing.

Anticancer research - 1 Sept 2024

Lee Hyunwoo, Cho Yoon Ah, Kim Deok Geun, Son Jae Young, Cho Eun Yoon

Abstract excerpt

BACKGROUND/AIM: TP53 mutation in breast cancer (BC) is associated with chemoresistance, endocrine therapy resistance, and late recurrence, resulting in poor prognosis. Nuclear accumulation of p53 in immunohistochemistry (IHC) is a surrogate marker of TP53 mutation. This study analyzed the frequency, type, and distribution of TP53 mutations in BCs and assessed the efficacy of p53 IHC as a surrogate marker of TP53...

Topics

Join the communities discussing this publication.

Biomarkers, Tumor
Breast Neoplasms
DNA Mutational Analysis
High-Throughput Nucleotide Sequencing
Immunohistochemistry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Triple Negative Breast Neoplasms

Tumor Suppressor Protein p53

Source

Identifiers

PMID: 39197898
DOI: 10.21873/anticanres.17227

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing.PMID 39197898Read ↗

P53 immunohistochemistry is an ideal surrogate marker for TP53 mutation and a predictor of early metastasis in breast cancer: Real-world analysisSemantic proximity Read ↗

Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple‐negative breast cancerSemantic proximity Read ↗

Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple-negative breast cancerSemantic proximity Read ↗

p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.Semantic proximity Read ↗

p53 protein expression patterns associated with TP53 mutations in breast carcinoma.Semantic proximity Read ↗

Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations.Semantic proximity Read ↗

Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.Semantic proximity Read ↗

Therapeutic landscape in mutational triple negative breast cancerSemantic proximity Read ↗

A Retrospective Study of the Correlation Between Next-Generation Sequencing and Immunohistochemical Detection of TP53 in Colorectal Cancer.Semantic proximity Read ↗

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.Semantic proximity Read ↗

Correlative assessment of p53 immunostaining patterns and TP53 mutation status by next-generation sequencing in lung adenocarcinoma (LUAD).Semantic proximity Read ↗

Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.